Storia della carriera di Mann Muhsin
Precedenti posizioni note di Mann Muhsin
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MEDICENNA THERAPEUTICS CORP. | Direttore Tecnico/Scientifico/R&S | 12/05/2021 | 17/01/2022 |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/04/2019 | 01/04/2020 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2016 | 01/03/2019 |
Formazione di Mann Muhsin
| University of Baghdad | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Canada | 2 |
| Iraq | 2 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MEDICENNA THERAPEUTICS CORP. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Mann Muhsin
- Esperienza
